ClinicalTrials.gg
CompletedNCT03789578Updated Nov 12, 2024

A Research Study to Look at How Insulin 287 and Semaglutide Work in the Body of People With Type 2 Diabetes When Taken Alone or Together

A Phase 1 interventional study of NNC0148-0287sema and Semaglutide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2024-11-12.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
21st of 27
30 · median 84
Started
2019
with 3 others
Phase 1
13 of 27
none open now
Registered
6th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 21st largest by enrollment, is one of 4 that started in 2019, is one of 13 in phase 1, and was the 6th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The study will look at how insulin 287 and semaglutide work in the body, both when given alone or together. This study will look at the way insulin 287 and semaglutide reach and stay in participants' blood after injection when given alone or together. Participants will get 3 study medicines at 3 different time points: 1) a combination of semaglutide plus insulin 287, 2) insulin 287 alone and 3) semaglutide alone. The order in which participants get them is decided by chance. Participants will get all medicines as an injection under the skin in the thigh. The injections will be done by study staff. The time between injections is 6 to 9 weeks. The study will last for about 19 to 32 weeks in total.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18-64 years (both inclusive) at the time of signing
  • Diagnosed with type 2 diabetes mellitus more than or equal to 180 days prior to the day of screening
  • Body weight between 80.0 to 120.0 kg (both inclusive)
  • Glycosylated () 6.0 to 8.5% (both inclusive)
  • No current and no regular previous intake of insulin. Previous insulin treatment for short periods of time (a maximum of 14 days) is allowed, as well as insulin use during a previous period of gestational diabetes in the past (as declared by the subject or reported in the medical records)
  • Stable daily dose(s) of the following anti-diabetic drug(s)/regimen within the past 90 days prior to the day of screening: a) Any metformin formulation (dose as documented in the subject medical record), b) One other oral antidiabetic drug (dose as documented in the subject medical record) is allowed, but not mandatory: Insulin secretagogue (sulphonylureas), dipeptidyl peptidase 4 (DPP-4) inhibitor and sodium glucose co-transporter 2 (SGLT2) inhibitor

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to trial products or related products
  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate methods
  • Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event within the past 180 days) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis within the past 180 days prior to the day of screening
  • Receipt of any medicinal product within 90 days before screening
  • History of severe allergies to drugs or foods or a history of severe anaphylactic reaction
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Semaglutide plus insulin 287

    Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)).

    Drug: NNC0148-0287sema

  • Experimental
    Semaglutide alone

    Participants will get a single dose of semaglutide (treatment B) alone.

    Drug: Semaglutide

  • Experimental
    Insulin 287 alone

    Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone.

    Drug: NNC0148-0287

Interventions

  • DrugNNC0148-0287sema

    Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen.

  • Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.

    Also known as: Ozempic®

  • Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen.

06

What researchers measure

Primary outcomes

  1. AUCI287, 0-tz, area under the serum insulin 287 concentration-time curve from 0 hours to last quantifiable observation after a single dose

    Measured in pmol\*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.

    Time frame: 0-840 hours

  2. AUCSema,0-tz, area under the plasma semaglutide concentration-time curve from 0 hours to last quantifiable observation after a single dose

    Measured in pmol\*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.

    Time frame: 0-840 hours

Secondary outcomes

  1. AUCI287,0-∞ area under the serum insulin 287 concentration-time curve from 0 hours to infinity after a single dose

    Measured in pmol\*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.

    Time frame: 0-840 hours

  2. Cmax, I287, maximum observed serum insulin 287 concentration after a single dose

    Measured in pmol/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.

    Time frame: 0-840 hours

  3. tmax, I287, time to maximum observed serum insulin 287 concentration after a single dose

    Measured in hour (h) for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.

    Time frame: 0-840 hours

  4. AUCSema,0-∞, area under the plasma semaglutide concentration-time curve from 0 hours to infinity after a single dose

    Measured in pmol\*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.

    Time frame: 0-840 hours

  5. Cmax,Sema, maximum observed plasma semaglutide concentration after a single dose

    Measured in pmol/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.

    Time frame: 0-840 hours

  6. tmax,Sema, time to maximum observed plasma semaglutide concentration after a single dose

    Measured in hour (h) for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.

    Time frame: 0-840 hours

  7. Number of treatment emergent adverse events

    Count of events.

    Time frame: Day 1 (beginning of each period) to day 36 (end of each period)

  8. Number of hypoglycaemic episodes

    Count of episodes.

    Time frame: Day 1 (beginning of each period) to day 36 (end of each period)

  9. Antibodies for insulin 287: Change in anti-insulin 287 binding antibody levels

    Measured as percentage B/T following administration of NNC0148 -0287sema and insulin 287.

    Time frame: Day -1 (pre-dose), Day 36 (end of period)

  10. Antibodies for insulin 287: Occurrence of anti-insulin 287 binding antibodies

    Percentage of events (yes/no) following administration of NNC0148 -0287sema and insulin 287.

    Time frame: Day 36 (end of period)

  11. Antibodies for insulin 287: Occurrence of anti-insulin 287 binding antibodies cross reacting to human insulin

    Percentage of events (yes/no) following administration of NNC0148 -0287sema and insulin 287.

    Time frame: Day 36 (end of period)

  12. Antibodies for semaglutide: Change in anti-semaglutide binding antibody levels

    Measured as percentage B/T following administration of NNC0148 -0287sema

    Time frame: Day -1 (pre-dose), Day 36 (end of period)

  13. Antibodies for semaglutide: Occurrence of anti-semaglutide binding antibodies

    Percentage of events (yes/no) following administration of NNC0148 -0287sema.

    Time frame: Day 36 (end of period)

  14. Antibodies for semaglutide: Occurrence of anti-semaglutide binding antibodies cross reacting to endogenous glucagon-like peptide-1 (GLP-1)

    Percentage of events (yes/no) following administration of NNC0148 -0287sema.

    Time frame: Day 36 (end of period)

  15. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Anti-semaglutide binding antibody levels

    Measured as percentage B/T.

    Time frame: Day 151 (follow-up/end-of-trial visit)

  16. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide binding antibodies cross reacting to endogenous GLP-1

    Percentage of events (yes/no).

    Time frame: Day 151 (follow-up/end-of-trial visit)

  17. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Anti-insulin 287 binding antibody levels

    Measured as percentage B/T.

    Time frame: Day 151 (follow-up/end-of-trial visit)

  18. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-insulin 287 binding antibodies cross reacting to human insulin

    Percentage of events (yes/no).

    Time frame: Day 151 (follow-up/end-of-trial visit)

  19. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies

    Percentage of events (yes/no).

    Time frame: Day 151 (follow-up/end-of-trial visit)

  20. Binding antibodies and in vitro neutralising antibodies (semaglutide only): Occurrence of anti-semaglutide neutralising antibodies cross reacting with endogenous GLP-1

    Percentage of events (yes/no).

    Time frame: Day 151 (follow-up/end-of-trial visit)

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, 41460, Germany
08

References and documents

Publications

  • Westergaard L, Alifrangis L, Buckley ST, Coester HV, Klitgaard T, Kristensen NR, Nishimura E, Norgreen L, Rocha TMP, Steensgaard DB, Vegge A, Plum-Morschel L. Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus. Clin Drug Investig. 2024 Nov;44(11):849-861. doi: 10.1007/s40261-024-01405-8. Epub 2024 Nov 3. PubMed 39488821 ↗

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · www.novonordisk-trials.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Oct 2019, 8 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 8 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2018
First posted
Dec 28, 2018
StartActual
Jan 17, 2019
Primary completionActual
Oct 10, 2019
CompletionActual
Oct 10, 2019
Last update
Nov 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03789578
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 28, 2018
Start date
Jan 17, 2019
Primary completion
Oct 10, 2019
Completion
Oct 10, 2019
Last update
Nov 12, 2024

Study contacts

Clinical Reporting Anchor and Disclosure (1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin icodec

Start the discussion